$RDC (-2,93%) Always good for a swing trade thanks to the nice volatility. I am starting again with a tranche around €2,000 / €126.90

It still has some downside potential, but I've got one foot in. Should the level around €116 be reached. It will be built up again.

Analsyst updates, 08.11.

⬆️⬆️⬆️

- GOLDMAN upgrades BIONTECH from Neutral to Buy and raises price target from USD 90 to USD 137. $BNTX (+0,04%)

- BOFA raises target price for UNDER ARMOUR from USD 9 to USD 13. Neutral. $UAA (+1,89%)

- DEUTSCHE BANK RESEARCH raises the price target for DELIVERY HERO from EUR 29 to EUR 35. Hold. $DHE

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS from EUR 197 to EUR 200. Buy. $SIE (-1,02%)

- JEFFERIES raises the price target for HOCHTIEF from EUR 135 to EUR 138. Buy. $HOT (+0,95%)

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS HEALTHINEERS from EUR 60 to EUR 62. Buy. $SHL (+0,12%)

- DEUTSCHE BANK RESEARCH raises the price target for NORDEX from EUR 18 to EUR 19. Buy. $NDX1 (+1,32%)

- DEUTSCHE BANK RESEARCH raises the price target for RATIONAL from 832 EUR to 841 EUR. Hold. $RAA (-0,91%)

- DEUTSCHE BANK RESEARCH raises the target price for AXA from 37 EUR to 39 EUR. Buy. $CS (-2,07%)

- WARBURG RESEARCH raises the price target for BASTEI LÜBBE from EUR 11.70 to EUR 12.20. Buy. $BST (+2,93%)

- DEUTSCHE BANK RESEARCH raises the price target for ARCELORMITTAL from EUR 28 to EUR 29. Buy. $MT (-3,63%)

- DZ BANK raises the price target for SWISS RE from CHF 130 to CHF 140. Buy. $SREN (+0,52%)

- ODDO BHF raises the price target for HEIDELBERG MATERIALS from EUR 99 to EUR 110. Neutral. $HEI (-0,21%)

- KEPLER CHEUVREUX raises the price target for DAIMLER TRUCK from EUR 35 to EUR 41. Hold. $DTG (-0,8%)

- KEPLER CHEUVREUX upgrades REDCARE PHARMACY from Reduce to Hold. $RDC (-2,93%)

- ODDO BHF raises the price target for HENKEL from EUR 67 to EUR 73. Neutral. $HEN (-1,02%)

- ODDO BHF raises the price target for FREENET from EUR 27 to EUR 28. Neutral. $FNTN (+0,68%)

- BARCLAYS raises the target price for ABOUT YOU from EUR 3.10 to EUR 3.40. Underweight. $YOU (-0,23%)

- BARCLAYS raises the target price for NEMETSCHEK from EUR 108 to EUR 125. Overweight. $NEM (-0,42%)

⬇️⬇️⬇️

- BOFA lowers the price target for PINTEREST from USD 45 to USD 39. Buy. $PINS

- WARBURG RESEARCH lowers the price target for DAIMLER TRUCK from EUR 56 to EUR 55. Buy. $DTG (-0,8%)

- UBS lowers the price target for JCDECAUX from EUR 21.60 to EUR 18.50. Neutral. $DEC (-1,97%)

- WARBURG RESEARCH lowers the price target for ADTRAN HOLDING from EUR 9.70 to EUR 9.30. Buy. $ADTN (+4,3%)

- ODDO BHF lowers the price target for NORDEX from EUR 18 to EUR 17. Outperform. $NDX1 (+1,32%)

- BARCLAYS lowers the target price for VESTAS from DKK 99 to DKK 80. Underweight. $VWS (+1,45%)

- KEPLER CHEUVREUX lowers the price target for FRAPORT from EUR 62 to EUR 59. Buy. $FRA (-0,59%)

- BARCLAYS lowers the target price for GSK from GBP 15.50 to GBP 14.50. Equal-Weight. $GSK

- BERENBERG lowers the price target for COMPUGROUP from EUR 23 to EUR 21. Buy. $COP (+0,18%)

- BERENBERG lowers the price target for JUNGHEINRICH from EUR 41 to EUR 39. Buy. $JUN3 (-0,32%)

- JEFFERIES lowers the target price for SUSS MICROTEC from EUR 87 to EUR 75. Buy. $SMHN (+0,96%)

08.11.2024

US Federal Reserve lowers key interest rate by 25 basis points
+ Goldman raises Biontech to 'Buy' - target up to 137 dollars + Bechtle higher - remains optimistic for the final quarter + Redcare at three-year high

The US Federal Reserve has lowered its key interest rate by 25 basis points. This decision had been firmly expected on the markets. The decision was taken unanimously by the Federal Open Market Committee (FOMC). The decision, which was taken in the week of Donald Trump's re-election as US president, followed an initial cut of 50 basis points in September and will bring the key interest rate to a range of 4.50 to 4.75 percent. US Federal Reserve officials have said that these rate cuts are justified because they are more confident that inflation will return to the central bank's target and because they believe that interest rates are still high enough to dampen economic activity even after the recent cuts. "The Council judges that the risks to achieving the employment and inflation objectives are roughly balanced," the Fed's statement said. Trump's election victory has the potential to reshape the economic outlook as the Republicans' likely majority in Congress allows for a sweeping change of course on taxes, spending, immigration and trade. The changing outlook has in turn raised questions on Wall Street as to whether the Fed will change its previous expectation that interest rates could be steadily lowered over the next year or two.

The US investment bank Goldman Sachs has Biontech $BNTX (+0,04%) from "Neutral" to "Buy" and raised its price target from 90 to 137 US dollars. Analyst Chris Shibutani now includes BNT327 - an antibody that the Mainz-based company is testing against various solid tumors - in his buy recommendation published on Friday. The investment story is moving further away from the difficult-to-assess Covid vaccine market.

With Bechtle $BC8 (-1,63%) a very weak 2024 share was in demand in pre-market trading on Friday. Following the IT service provider's final quarterly figures, the shares rose by 2.7 percent in Tradegate trading compared to the Xetra closing price. An attempt to recover from the low since 2020 thus continues. So far this year, the share has lost around 28% despite the recent stabilization and a gain of 3.3% the day before. Since the record high in 2021, the share price has even more than halved. According to a trader, the business environment for Bechtle in the third quarter was characterized by challenges. The results showed a mixed picture with weak demand in the core markets of Germany and France, but solid organic growth in other international markets, and another trader emphasized that Bechtle is optimistic about the future and continues to expect an improvement in the fourth quarter. However, the first mentioned trader sees risks in the fact that public IT spending in Germany could suffer for the time being from the end of the traffic light coalition.

The good performance of the shares of Redcare Pharmacy $RDC (-2,93%) continued on Friday with a high since December 2021. The shares were already the biggest MDax gainer in 2023 and are among the better performers in the mid-cap index this year. On Friday, they rose by up to three percent to EUR 157.60 in early Xetra trading. So far this year, they have repeatedly struggled in the EUR 153 to 154 range.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Apple USD 0.25

Pfizer USD 0.42

ConocoPhillips USD 0.78

Wells Fargo USD 0.4

Quarterly figures / company dates USA / Asia

07:00 Sony quarterly figures

Untimed: Baxter International quarterly figures

Quarterly figures / Company dates Europe

07:00 LEG Immobilien | Richemont Quarterly figures

07:30 Bechtle | Deutsche Wohnen Quarterly figures

08:00 Banca Monte dei Paschi | International Consolidated Airlines Quarterly figures

10:00 Freenet earnings call and strategy update until 2028

10:30 Bechtle analyst and press conference

14:00 Pernod Ricard AGM

Economic data

• 06:00 JP: Leading indicators 9/24 (preliminary)
• 08:00 DE: Domestic tourism | Truck toll mileage index October
• 09:00 DE: Bundestag, Plenum, Berlin
• 11:30 DE: Government Pk, Berlin
• 16:00 US: Consumer Sentiment Index Uni Michigan (1st survey) November FORECAST: 71.0 previous: 70.5

Redcare Pharmacy Q3 2024 $RDC (-2,93%)

Financial performance

• Sales growth: Group sales increased by 33.8% to EUR 1.7 billion in the first nine months of 2024. Excluding MediService, growth amounted to 23 %.
• Growth in non-prescription products: Sales of non-prescription products grew by 20 % to 1.2 billion euros.
• Prescription sales in Germany: Growth in prescription drugs was particularly notable, with an increase of 7 % in the first quarter, 37 % in the second quarter and 81 % in the third quarter.

Balance sheet overview

• Total assets: Remained stable at 1.0 billion euros, unchanged compared to year-end 2023.
• Current assets: Increased by 16.6 million euros to 516.1 million euros, with inventories rising to 142.4 million euros.
• Cash and cash equivalents: Increased to 99.4 million euros.

Details of the income statement

• Adjusted EBITDA: Increased slightly to 38 million euros in the first nine months of 2024.
• Gross margin: Decreased year-on-year from 25.2% to 23.3%.

Cash flow overview

• Operating cash flow: Positive at 39.1 million euros, compared to 69.6 million euros in the previous year.
• Investing activities: Net amount of -9.3 million euros.
• Financing activities: Outflow of 14.9 million euros.

Key figures and profitability metrics

• Adjusted EBITDA margin: Decreased to 2.3% year-to-date.
• Sales and distribution margin: Improved to 18.2% from 19.4% year-on-year.

Segment information

• DACH segment: Sales of 1.376 billion euros with a gross profit of 315.5 million euros.
• International segment: Sales of 319.4 million euros with a gross profit of 79.8 million euros.

Competitive position

• Market share in Germany: Doubled from January to the end of the third quarter, with further acceleration into the fourth quarter.

Management forecasts and comments

• Management updated the full-year guidance on October 3, pointing to strong e-Rx metrics as the basis for the accelerated development.

Risks and opportunities

• The report highlights seasonal effects and general business expansion as factors impacting trading and other liabilities.

Summary of results

The company showed robust sales growth, particularly in the prescription segment in Germany. Despite a slight decline in gross margins, the overall financial position remains stable, with increased cash resources. The company is strategically well positioned to benefit from the growing e-Rx market, which is reflected in the increased market share. Nevertheless, the decline in operating cash flow and the need for continued investment in IT and infrastructure indicates areas that need to be carefully managed financially.

Positive Aspects

• Strong sales growth: The company recorded significant sales growth of 33.8% in the first nine months of 2024, with total sales of EUR 1.7 billion. This growth was driven by both prescription and over-the-counter sales.
• Increased market share in Germany: The company's market share in the German e-Rx segment increased significantly from 0.27% in January to 0.66% in October, indicating a strong competitive position.
• Growth in cash and equivalents: Cash and cash equivalents increased to €99.4 million, reflecting a solid liquidity position.
• Improved sales and distribution margin: The sales and distribution margin improved to 18.2% from 19.4% in the previous year, indicating better cost management in these areas.
• Expansion of the customer base: The company added 1.4 million active customers year-on-year to reach a total of 11.9 million active customers, supporting future revenue growth.

Negative aspects

• Decline in gross margin: Gross margin decreased year-on-year from 25.2% to 23.3%, which could indicate pricing pressure or increased cost of goods sold.
• Decline in operating cash flow: Operating cash flow decreased to €39.1 million compared to €69.6 million in the previous year, indicating potential challenges in generating cash from operations.
• Lower adjusted EBITDA margin: The adjusted EBITDA margin fell to 2.3% year-to-date, indicating reduced profitability.
• Increase in trade and other payables: There was an increase in trade and other payables of €23.7 million, which could indicate higher liabilities due to seasonal effects and business expansion.
• Higher capital expenditure: Net expenditure on investing activities amounted to -9.3 million euros, indicating increased capital expenditure. This could put pressure on cash reserves if it is not accompanied by corresponding sales growth.

Analyst updates, 05.11.

⬆️⬆️⬆️

- ODDO BHF raises the price target for BIONTECH from USD 110 to USD 130. Outperform. $BNTX (+0,04%)

- BARCLAYS raises the price target for AIRBUS from EUR 161 to EUR 165. Overweight. $AIR (-0,6%)

- CITIGROUP raises the price target for SCOUT24 from EUR 91 to EUR 94.50. Buy. $G24 (-0,32%)

- WARBURG RESEARCH raises the price target for REDCARE PHARMACY from EUR 174 to EUR 176. Buy. $RDC (-2,93%)

- DEUTSCHE BANK RESEARCH raises the price target for RYANAIR from EUR 17 to EUR 17.50. Hold. $RYA (-0,9%)

- BERNSTEIN rates EBAY from Market-Perform to Outperform. Target price USD 70. $EBAY (-1,68%)

- ODDO BHF raises the price target for SALZGITTER from EUR 14 to EUR 15.50. Underperform. $SZG (-1,46%)

- BARCLAYS raises the target price for COMMERZBANK from EUR 16 to EUR 17. Equal-Weight. $CBK (+1,05%)

- BARCLAYS raises the target price for MTU from EUR 295 to EUR 340. Equal-Weight. $MTX (-1,28%)

- MORGAN STANLEY rates LUFTHANSA to Equal-Weight. Target price EUR 7. $LHA (-1,12%)

- BERENBERG raises the price target for DEUTSCHE KONSUM REIT from EUR 3.50 to EUR 5. Hold.

⬇️⬇️⬇️

- GOLDMAN lowers the price target for MERCEDES-BENZ from EUR 65 to EUR 63. Buy. $MBG (-0,82%)

- UBS lowers target price for 1&1 from EUR 21.60 to EUR 21. Buy.

- WARBURG RESEARCH lowers the price target for GFT TECHNOLOGIES from EUR 40 to EUR 37.50. Buy. $GFT (-0,88%)

- HAUCK AUFHÄUSER IB lowers the price target for ECKERT & ZIEGLER from EUR 63.50 to EUR 55. Buy. $EUZ (-1,21%)

- BARCLAYS lowers the price target for BNP PARIBAS from EUR 90 to EUR 85. Overweight. $BNP (-0,47%)

- BERENBERG downgrades SCHNEIDER ELECTRIC from Buy to Hold and lowers price target from EUR 261 to EUR 255. $SU (-0,02%)

- BERENBERG lowers the price target for BEFESA from EUR 41 to EUR 31. Buy. $BFSA (-1,52%)

Earnings summary this morning (05.11.) 👇🏼

Krones | $KRN (+0%) increases both sales and operating profit in the third quarter, with EBITDA growing by almost 22% to almost 135 million euros. The company confirms its forecast and benefits from improved material availability.

Uniper | $UN01 generates a profit of just under EUR 1.3 billion in the first nine months of 2024, but significantly less than in the previous year. The energy group confirms its outlook for the year with an expected net profit of EUR 1.1 to 1.5 billion.

Hugo Boss | $BOSS (-3,44%) recorded a slight increase in sales of 1% to 1.03 billion euros in the third quarter despite a slump in consumption in China, but EBIT fell by 7% to 95 million euros. The Group confirms its annual targets despite higher sales and marketing costs.

Fraport | $FRA (-0,59%) is lowering its expectations for passenger numbers in 2024 to the lower end of the range of 61 million passengers and is targeting EBITDA in the middle of the previous forecast of 1.26 to 1.36 billion euros. In the summer quarter, revenue rose by 11%, while operating profit only increased by 1%.

Fresenius Medical Care | $FRE (+0,34%) increases operating profit in the third quarter by 43 % to 463 million euros, which is attributable to successful cost savings. The company raises its forecast for adjusted operating profit, but expects a slight decline in sales.

Redcare Pharmacy | $RDC (-2,93%) reports a decline in adjusted EBITDA to 11.4 million euros in the third quarter and increases the loss for the first nine months to 20.1 million euros. The company confirms adjusted annual targets and expects a lower operating profit due to higher advertising expenditure for the e-prescription.

DHL | $DHL (-0,9%) reports a decline in profit of almost 7% to 751 million euros for the third quarter and lowers its forecast for operating profit in 2024 and 2026. Revenue increases by 6% to 20.6 billion euros, while EBIT remains stable at 1.4 billion euros.

Norma Group | $NOEJ (+0,6%) is revising its annual targets downwards and now expects sales of around EUR 1.2 billion and an adjusted EBIT margin of around 8.0 percent due to a challenging market environment. In the third quarter, the company recorded a decline in sales of 7.9% to 273.6 million euros and a drop in profit to 6.1 million euros.

Nintendo | $7974 (+0,19%)
Q2 24 Earnings:

- Net Income 27.70B Yen (est 49.4B Yen)

- Sees FY Oper Income 360.00B Yen, Saw 400.00B Yen

- Sees FY Total Switch Sales 12.50M Units, Saw 13.50M

Adecco | $ADEN (+0,5%) 24 Earnings:

- Net Income EU99.0M (est EU86.8M)

- Rev EU5.70B (est EU5.84B)

- Adj EBITA EU186.0M (est EU195M)

- Plans To Repay EU430M Debt Maturing In Dec 24

25.10.2024

Lilium subsidiaries have to file for insolvency + Shop Apotheke and DocMorris pick up + US parcel service UPS earns more than expected + Bilfinger shares under pressure after tragedy in the USA

After the end of state support, Lilium announces Lilium $LILM (-17,81%) announces that its most important subsidiaries will file for bankruptcy. The air cab developer's share price then plummets by more than 58 percent.....

https://www.manager-magazin.de/unternehmen/aktien-von-lilium-mit-kurseinbruch-tochtergesellschaften-muessen-insolvenz-anmelden-a-c4e2581f-d5c9-4b8f-b60e-77e4051371ec

On Thursday, market observers pointed to positive signals in a court case involving mail-order pharmacies in the landmark proceedings over price discounts on prescription drugs. The shares of Redcare Pharmacy $RDC (-2,93%) extended their gains by up to five percent and were still up by almost four percent in the afternoon. The competitor DocMorris $DOCM (-1,16%)which at times extended its gains in Zurich to more than ten percent. DocMorris shares thus recovered strongly from the most recent low since June 2023. Redcare shares continued their recent rally. They have gained almost 30 percent since mid-September. However, they once again encountered resistance at the EUR 150 mark. Analyst Thomas Rothäusler from Jefferies pointed out that an attorney general had issued a final opinion in proceedings in which DocMorris is taking on the North Rhine Chamber of Pharmacists. This opinion was very clearly in favor of bonuses on prescription drugs. According to Rothäusler, the final result is likely to have a significant impact on the future growth of online pharmacies. According to the expert, the final ruling of the European Court of Justice is expected in the next two to three months.

The US parcel service UPS $UPS (-0,37%) earned a surprisingly high profit in the third quarter thanks to good business and the sale of a subsidiary. The bottom line was a profit of a good 1.5 billion US dollars (1.4 billion euros), around 37 percent more than a year earlier, as United Parcel Service (UPS) announced in Atlanta on Thursday. Even without the special effect, this was more than analysts had expected on average. For the year as a whole, however, CEO Carol Tomé is now expecting lower turnover because the sold subsidiary Coyote Logistics is no longer included in the figures. According to Tomé, the Group's turnover is only expected to reach around 91.1 billion dollars in 2024. She had previously forecast 93 billion. However, before special effects, a larger share of turnover is expected to remain as operating profit at UPS. The manager is therefore expecting an adjusted operating margin of around 9.6 percent. Previously, she had assumed 9.4 percent. In the third quarter, UPS reported a turnover of 22.2 billion dollars, 5.6 percent more than a year earlier. This was about as much as analysts had expected on average.

The collapse of a ferry dock in the USA caused the shares of Bilfinger $GBF (-0,92%) shares on Thursday. The share price fell by 6.8 percent to 46.25 euros. If this remains the case, it would be the biggest daily loss in almost two years. In a letter of condolence, Group CEO Thomas Schulz and the head of the US subsidiary Centennial Contractors Enterprises, Geoff Preisman, expressed their deepest sympathy to the families of seven people who reportedly lost their lives in the collapse of a ferry dock on October 19. The accident occurred on the island of Sapelo off the coast of the US state of Georgia. Centennial acted as the general contractor for the construction of the dock and pier in question, the statement continued. The company worked with local subcontractors and suppliers to complete the project in November 2021. Should Centennial, as the general contractor, have to assume liability for the accident, a payment of an estimated 50 to 100 million euros is imminent, said a stock market analyst. This scenario is weighing on the Bilfinger share price.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Fastenal USD 0.39

Quarterly figures / company dates USA / Asia

13:00 Colgate-Palmolive Quarterly figures

Quarterly figures / company dates Europe

06:30 Sika quarterly figures | Holcim | SGS Trading Update 3Q

07:00 Mercedes-Benz | Stratec | Signify quarterly figures | Safran sales 3Q

07:30 Sanofi quarterly figures | Remy Cointreau Q2 sales

07:45 Eni quarterly figures

08:00 Yara quarterly figures | Mercedes-Benz analyst conference

09:00 Holcim analyst and press conference

09:15 Mercedes-Benz PK

14:00 Sanofi Analyst Conference

17:30 Porsche AG quarterly figures and press conference

Economic data

01:30 JP: Consumer prices Greater Tokyo October core rate (ex food)

FORECAST: +1.7% yoy previously: +2.0% yoy

08:45 FR: Consumer Confidence October FORECAST: 95 previous: 95

10:00 DE: ifo Business Climate Index October PROGNOSE: 85.6 PREVIOUS: 85.4 Situation assessment PROGNOSE: 84.3 PREVIOUS: 84.4 Business expectations

PROGNOSE: 87.0 PREVIOUS: 86.3

10:00 EU: ECB - October consumer survey results | Publication of consumer survey results | ECB, M3 money supply and lending September M3 money supply FORECAST: +3.0% yoy previously: +2.9% yoy

14:30 US: New orders for durable goods September

PROGNOSE: -1.0% yoy previous: 0.0% yoy

16:00 US: Consumer Sentiment Index Uni Michigan (2nd survey) October

FORECAST: 69.0 1st survey: 68.9 previous: 70.1

09.10.2024

Samsung disappoints with weak quarterly figures + PepsiCo Inc. outperforms in the third quarter + SHARES IN THE FOCUS: DocMorris turns positive

The latest business figures from Samsung $SMSD (+1,62%) fall short of market expectations. In its quarterly outlook for the months of July to September, the South Korean electronics giant assumes that the operating profit of 9.1 trillion won (around 6.1 billion euros) has increased fourfold year-on-year. However, compared to the previous second quarter of the year, profits fell by almost 13 percent. The markets reacted with disappointment. Samsung's share price fell by more than 1.3 percent immediately after the publication of the quarterly outlook. Experts attribute the comparatively weak quarterly figures to the fact that the market leader for memory chips, smartphones and televisions is currently lagging behind in the development of high-performance semiconductors in the booming AI market. In particular, direct competitors Nvidia and SK Hynix are putting Samsung under heavy pressure. The business figures are only an initial estimate. The Group will only publish more precise figures at a later date, probably at the end of the month.

The shares of DocMorris $DOCM (-1,16%) turned clearly positive on Tuesday morning in a weak market environment. The shares of the Swiss competitor of Redcare Pharmacy $RDC (-2,93%) gained over 6 percent, while Redcare remained rather inconspicuously in the red. An article in "Apotheke Adhoc" entitled "Is Redcare going after DocMorris?" generated demand for DocMorris. According to the article, Redcare has now "left DocMorris far behind - and could even absorb it sooner or later".

PepsiCo Inc. $PEP (-0,88%) outperformed analysts' estimates of USD 2.29 with earnings per share of USD 2.31 in the third quarter.

• Sales of USD 23.32 billion below expectations of USD 23.9 billion.
• Due to product recalls and geopolitical tensions, Pepsico expects a slower increase in sales in the current financial year and only anticipates low single-digit growth.
• Pepsico is sticking to its earnings forecast and expects adjusted earnings per share of at least eight percent excluding currency effects and at least seven percent including currency effects to USD 8.15.
• Pepsico reported sales of USD 23.3 billion in the third quarter, down 0.6 percent year-on-year, while organic sales increased by 1.3 percent.
• In the third fiscal quarter, Pepsico earned USD 2.9 billion, five percent less than in the same period last year, due to product recalls at Quaker Foods and lower earnings at the snack division Frito-Lay.

Wednesday: Stock market dates, economic data, quarterly figures

Stock exchange holiday in South Korea

ex-dividend of individual stocks

Mastercard Registered (A) USD 0.66

Gap USD 0.15

Quarterly figures / company dates Europe

08:15 Traton Pre-Close Call 3Q

No time specified: Bechtle Capital Markets Day

Economic data

• 08:00 DE: Trade balance August trade balance calendar and seasonally adjusted PROGNOSE: +18.5bn euros previous: +16.8bn euros Exports PROGNOSE: -1.0% yoy previous: +1.7% yoy Imports PROGNOSE: -2.8% yoy previous: +5.4% yoy
• 14:00 US: Atlanta Fed President Bostic to speak at Greater Atlanta Home Builders Association event
• 16:00 US: Wholesale sales 8/24
• 16:30 US: EIA crude oil inventories previous week
• 20:00 US: Fed, minutes of FOMC meeting Sept. 17/18

$RDC (-2,93%) The Shopapotheke is already just as nice to trade as the $OMV (+0,83%) 😅🇦🇹

Fits well for my investment horizon (weeks - months) for my "risk capital".

Re-entered in the price range of the gap from July in September. And now the trailing SL has done its job again.

Edit: and what do you do if the price doesn't go back into the range downwards, but breaks out upwards shortly after the stop loss?

Then you can set an entry point with a stop buy. In this case, in addition to a new limit for entry at €116 on the downside, I also set a stop buy on the upside. I placed it in the €139 range. This was my exit level from the previous trade.

What happened to €100,000...

Or you could also say "Any monkey can beat the market" 😅

ttps://www.finanzen100.de/finanznachrichten/wirtschaft/wie-schimpansen-mit-dart-pfeilen-zu-den-besten-bankern-der-wall-street-wurden_H1960490147_546306/

At the end of the 3rd quarter, it's time for another update:

100,000€ invested from January of the respective year - B&H:

2022 Total return +43,526.00€ TTWROR 35.05% https://getqu.in/tcIuml/

2023 total return +€34,388.58 TTWROR 73.32% https://getqu.in/JjIr8V/

2024 Total return +€ 17,945.95 TTWROR 18.76% https://getqu.in/euJ994/

Highlights / Lowlights 2022:

$MELI (+3,46%) +142% / $META (+0,27%) +141% / $SAP (-1,02%) +100% / $RBLX -15%

Highlights / Lowlights 2023:

$RDC (-2,93%) +104% / $PAYC (+0,84%) -40%

Highlights / Lowlights 2024:

$ZAL (-0,36%) +76% / $9988 (+0,07%) +54% / $RKT (+0,31%) -10% / $KTN (-0,55%) -18%

For me, my 100k deposits are a nice (long-term) experiment. End of 2021 as #100kchallenge initiated for the year 2022. After the deep red 2022 year, I started the 2nd round in 2023 with only a few motivated people. Well, and in 2024 I started again on my own.

Now it's time to start thinking about 2025... Let's see which shares will go into my 2025 portfolio...🐵🐵🐵🐵